A regulatory acceptable alternative to E. coli : high yield recombinant protein production using the Lactococcus lactis P170 expression system combined with "Reverse electro enhanced dialysis" (REED) for lactate control

Søren M Madsen,Sean A Macdonald,Astrid Vrang,Arvid Garde,Jens-Ulrik Rype,Lars H Pedersen

doi:10.1186/1475-2859-5-s1-p80

Abstract

view on host physiology The organisers would like to thank Novozymes Delta Ltd who generously supported the meeting. Meeting

Highlights

The increasing demand for production of new recombinant pharmaceutical proteins constantly challenges our efforts to improve existing production systems or to develop new systems
The 4th Recombinant Protein Production Meeting: a comparative view on host physiology The organisers would like to thank Novozymes Delta Ltd who generously supported the meeting. Meeting abstracts – A single PDF containing all abstracts in this supplement is available here http://www.biomedcentral.com/content/pdf/1475-2859-5-S1-info.pdf
Bioneer has developed an alternative recombinant protein expression system, the P170 Expression System [1], which is based on the Gram positive lactic acid bacteria, Lactococcus lactis

Summary

Introduction

The increasing demand for production of new recombinant pharmaceutical proteins constantly challenges our efforts to improve existing production systems or to develop new systems. A regulatory acceptable alternative to E. coli: high yield recombinant protein production using the Lactococcus lactis P170 expression system combined with "Reverse Electro Enhanced Address: 1Bioneer A/S, Kogle Allé 2, DK-2970 Hørsholm, Denmark and 2JURAG Separation A/S, Gydevang 4, DK-3450 Allerød, Denmark * Corresponding author from The 4th Recombinant Protein Production Meeting: a comparative view on host physiology Barcelona, Spain.

Results

Conclusion